Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 32, Issue 2

Issues

One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty

Andrea J. Arcari
  • Corresponding author
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Analía V. Freire
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ María E. Escobar
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ María G. Ballerini
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ María G. Ropelato
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ignacio Bergadá
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mirta G. Gryngarten
  • Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo, Buenos Aires, Argentina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-01-30 | DOI: https://doi.org/10.1515/jpem-2018-0290

Abstract

Background

Puberty is associated with a physiological decline in insulin sensitivity (IS). Overweight (OW) and obesity (OB) are common among girls with central precocious puberty (CPP). CPP is considered a risk factor for metabolic diseases. The aim of this study was to assess surrogate measures of IS, body mass index (BMI) and other metabolic parameters in CPP girls at diagnosis and during treatment with gonadotropin-releasing hormone analogues (GnRHa).

Methods

We present a prospective longitudinal study of CPP girls. The standard oral glucose tolerance test, homeostatic model assessment of insulin resistance (HOMA-IR), whole-body IS index (ISI) and fasting lipid profiles were evaluated at diagnosis, and at 6 and 12 months of treatment.

Results

Nineteen CPP girls were included; 17 were evaluable. At baseline, seven patients had normal weight (NW), five were OW and five were OB. During GnRHa treatment no significant changes were observed in BMI, HOMA-IR or ISI when considering the whole group. Whereas, when we analyzed patients according to BMI status, in NW patients, BMI increased significantly with no changes in HOMA-IR or ISI along treatment. In the OW/OB group, no significant differences were observed in BMI, HOMA-IR or ISI.

Conclusions

Girls with CPP showed a high frequency of OW/OB and a high prevalence of IR. GnRHa did not affect BMI, IS or the lipid profile when considering the whole cohort of patients. However, there was an increase in BMI in NW girls but not in OW/OB patients.

Keywords: body mass index; central precocious puberty; GnRH analogues; insulin resistance; lipid profile

References

  • 1.

    Parent AS, Franssen D, Fudvoye J, Gérard A, Bourguignon JP. Developmental variations in environmental influences including endocrine disruptors on pubertal timing and neuroendocrine control: revision of human observations and mechanistic insight from rodents. Front Neuroendocrinol 2015;38:12–36.CrossrefWeb of SciencePubMedGoogle Scholar

  • 2.

    Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001;50:2444–50.PubMedCrossrefGoogle Scholar

  • 3.

    Palmert MR, Mansfield MJ, Crowley Jr WF, Crigler Jr JF, Crawford JD, et al. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480–8.PubMedGoogle Scholar

  • 4.

    Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626–34.PubMedCrossrefGoogle Scholar

  • 5.

    Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, et al. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463–4.CrossrefPubMedGoogle Scholar

  • 6.

    Tascilar ME, Bilir P, Akinci A, Kose K, Akcora D, et al. The effect of gonadotropin-releasing hormone analog treatment (leuprolide) on body fat distribution in idiopathic central precocious puberty. Turk J Pediatr 2011;53:27–33.PubMedGoogle Scholar

  • 7.

    Arcari AJ, Gryngarten MG, Freire AV, Ballerini MG, Ropelato MG, et al. Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. J Pediatr Endocrinol 2016;15:1–7.Web of ScienceGoogle Scholar

  • 8.

    Garn SM, LaVelle M, Rosenberg KR, Hawthorne VM. Maturational timing as a factor in female fatness and obesity. Am J Clin Nutr 1986;43:879–83.PubMedCrossrefGoogle Scholar

  • 9.

    Lakshman R, Forouhi N, Luben R, Bingham S, Khaw K, et al. Association between age at menarche and risk of diabetes in adults: results from the EPIC-Norfolk cohort study. Diabetology 2008;51:781–6.CrossrefGoogle Scholar

  • 10.

    Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 2009;94:4953–60.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 11.

    Golub MS, Collman GW, Foster PM, Kimmel CA, Rajpert-De Meyts E, et al. Public health implications of altered puberty timing. Pediatrics 2008;121(Suppl 3):S218–30.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 12.

    Remsberg KE, Demerath EW, Schubert CM, Chumlea WC, Sun SS, et al. Early menarche and the development of cardiovascular disease risk factors in adolescent girls: the Fels Longitudinal Study. J Clin Endocrinol Metab 2005;90:2718–2724.PubMedCrossrefGoogle Scholar

  • 13.

    Raitakari OT, Porkka KV, Rönnemaa T, Knip M, Uhari M, et al. The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study. Diabetologia 1995;38:1042–1050.CrossrefPubMedGoogle Scholar

  • 14.

    Boot AM, De Muinck K-SS, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 1998;83:370–3.PubMedGoogle Scholar

  • 15.

    Feuillan P, Jones J, Barnes K, Oerter-Klein K, Cutler Jr G. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44–9.PubMedCrossrefGoogle Scholar

  • 16.

    Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, et al. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab 2000;13(Suppl 1):791–4.PubMedGoogle Scholar

  • 17.

    Chiocca E, Dati E, Baroncelli GI, Mora S, Parrini D, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology 2009;89:441–7. DOI: 10.1159/000197862. Epub 2009 Jan 29.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 18.

    Anık A, Çatlı G, Abacı A, Böber E. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab 2015;19:267–71.PubMedCrossrefGoogle Scholar

  • 19.

    Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583–90.PubMedGoogle Scholar

  • 20.

    Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002;87:2090–4.PubMedCrossrefGoogle Scholar

  • 21.

    Glab E, Barg E, Wikiera B, Grabowski M, Noczyńska A. Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab 2009;15:7–11.PubMedGoogle Scholar

  • 22.

    Ko JH, Lee HS, Lim JS, Kim SM, Hwang JS. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist. Horm Res Paediatr 2011;75:174–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 23.

    van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506–12.CrossrefPubMedGoogle Scholar

  • 24.

    Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533–7.PubMedCrossrefGoogle Scholar

  • 25.

    Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011;27:524–8.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 26.

    Sorensen K, Mouritsen A, Mogensen SS, Aksglaede L, Juul A. IS and lipid profiles in girls with central precocious puberty before and during gonadal suppression. J Clin Endocrinol Metab 2010;95:3736–3744.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 27.

    Colmenares A, Gunczler P, Lanes R. Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. Int J Pediatr Endocrinol 2014;2014:5. DOI: 10.1186/1687-9856-2014–5.CrossrefPubMedGoogle Scholar

  • 28.

    Park J, Kim JH. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2017;22:27–35.CrossrefPubMedGoogle Scholar

  • 29.

    Freire AV, Gryngarten MG, Ballerini MG, Arcari AJ, Escobar ME, et al. Assessment of estradiol response after depot triptorelin administration in girls with central precocious puberty. Horm Res Paediatr 2016;85:58–64.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 30.

    Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.PubMedCrossrefGoogle Scholar

  • 31.

    Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Palo Alto, CA: Stanford University Press; 1959.Google Scholar

  • 32.

    Cole TJ, Bellizi MC, Fiegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J 2000;320:1240–3.CrossrefGoogle Scholar

  • 33.

    Browning L, Hsieh S, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev 2010; 23:247–69.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 34.

    Ballerini MG, Bergadá I, Rodríguez ME, Keselman A, Bengolea VS, et al. Insulin level and IS indices among healthy children and adolescents. Arch Argent Pediatr 2016;114:329–36.Web of SciencePubMedGoogle Scholar

  • 35.

    Matsuda M, DeFronzo RA. IS indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70.CrossrefPubMedGoogle Scholar

  • 36.

    Arancibia C, Galgani J, Valderas JP, Morales M, Santos JL, et al. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance Rev Med Chile 2014;142:1106–12.Web of ScienceGoogle Scholar

  • 37.

    Araujo MB, Casavalle P, Tonietti M, Ozuna B, Andres ME, et al. Comité de nutrición: Consensus on management of dyslipidemia in pediatrics. Arch Argent Pediatr 2015;13:177–86.Google Scholar

  • 38.

    Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, et al. Use of the oral glucose tolerance test to assess insulin release and IS. Diabetes Care 2000;23:295–301.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Andrea J. Arcari, MD, Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo 1330, C1425EFD Buenos Aires, Argentina, Tel: +5411-4963-5931 ext 127, Fax: +5411-4963-5930, E-mail: ajarcari@hotmail.com


Received: 2018-07-29

Accepted: 2018-12-16

Published Online: 2019-01-30

Published in Print: 2019-02-25


Acknowledgments

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This research was partially sponsored by the “Consejo de Investigación en Salud, Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires (CIS-GCBA)” to M.G.G.

Employment or leadership: M.G.G., M.G.B., I.B. and M.G.R. are research members at the “Carrera de Investigador en Salud, Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires”.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 32, Issue 2, Pages 181–186, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2018-0290.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in